Two-Year Lenalidomide Maintenance Matches Indefinite Therapy in Standard-Risk Myeloma
This phase 3 trial provides the first prospective randomized evidence that fixed 2-year lenalidomide maintenance yields overall survival equivalent to indefinite therapy in transplant-deferred standard-risk newly diagnosed multiple myeloma.
Two-year lenalidomide is as effective as indefinite therapy in multiple myeloma.
Determining the optimal duration of maintenance therapy in multiple myeloma could impact patient quality of life and resource allocation. Indefinite lenalidomide therapy did not extend overall survival compared to a fixed 2-year regimen, with similar outcomes after a 7-year median follow-up. This study suggests that extending lenalidomide beyond 2 years may not provide additional survival benefits in standard-risk patients, influencing treatment duration guidelines. Fixed 2-year lenalidomide maintenance is as effective as indefinite therapy in standard-risk multiple myeloma.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Kumar S, Jacobus S, Cohen A, Weiss M, Callander N, Singh A, Parker T, Green M, Thertulien R, Parsons B, Kumar P, Kapoor P, Rosenberg A, Dib E, Almquist D, Zonder J, Faber E, Wei Z, Anderson K, Lonial S, Richardson P, Orlowski R, Wagner L, Rajkumar SV
Citation:Kumar S, Jacobus S, Cohen A, et al. Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma. The New England journal of medicine. 2026;395(3):221-232. doi:10.1056/NEJMoa2600157